Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma.
Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma.
复制标题
DOI：
10.1016/j.ygyno.2015.10.012
复制
发表时间：
2015-12
影响因子：
4.7
通讯作者：
Iijima S
中科院分区：
文献类型：
--
作者：
Mikami M;Tanabe K;Matsuo K;Miyazaki Y;Miyazawa M;Hayashi M;Asai S;Ikeda M;Shida M;Hirasawa T;Kojima N;Sho R;Iijima S
虽然一部分子宫内膜异位瘤可发展为新生上皮性卵巢癌（EOC），如透明细胞癌（OCCC），但目前还没有有用的生物标志物可用于早期检测子宫内膜异位瘤中的OCCC。本研究的目的是描述一种新的生物标志物的诊断功能，特别是用于区分OCCC和子宫内膜异位瘤。从134例预处理的所有阶段EOC患者（包括45例occc）和159例非癌症对照女性（包括36例子宫内膜异位瘤）中获得的10万多个血清糖蛋白聚糖结构进行了质谱分析。通过比较曲线下面积（AUC）和阳性/阴性预测值（PPV和NPV），比较鉴定的生物标志物与CA-125的诊断准确性。A2160是一个完全唾液化的补体4结合蛋白α链，被确定为候选靶标。与子宫内膜异位瘤相比，A2160在OCCC的所有阶段均显著升高。A2160（临界值1.6 U/mL）区分早期OCCC和子宫内膜异位瘤的诊断准确性显著高于CA-125（临界值35 IU/L）： A2160的AUC与CA-125相比，分别为0.92和0.67；PPV 95% vs 64%；净现值是85%对58%。此外，与补体4结合蛋白α链的部分唾液化聚糖相比，全唾液化聚糖对EOC的诊断准确性更高。我们的研究提示A2160可能是区分早期OCCC和子宫内膜异位瘤的有用生物标志物。这种新的生物标志物可以潜在地用于子宫内膜异位瘤患者的监测，使OCCC的早期诊断成为可能。
While a certain fraction of endometriomas can develop de novo epithelial ovarian cancer (EOC) such as clear cell carcinoma (OCCC), there is currently no useful biomarker available for early detection of OCCC from endometriomas. The aim of this study was to describe the diagnostic utility of a novel biomarker for EOC especially for OCCC to distinguish from endometrioma. More than 100,000 glycan structures of serum glycoproteins obtained from 134 pretreatment all stage EOC patients (including 45 OCCCs) and 159 non-cancer control women (including 36 endometriomas) were explored for a mass spectrum approach. Diagnostic accuracy of identified biomarker was compared to the one of CA-125 by comparing area under curve (AUC) and positive/negative predictive values (PPV and NPV). A2160, a fully-sialylated alpha-chain of complement 4-binding protein, was identified as a candidate target marker. A2160 was significantly elevated in all stages of OCCC compared to with endometriomas. Diagnostic accuracy of A2160 (cutoff 1.6 U/mL) to distinguish early stage OCCC from endometrioma is significantly higher than that of CA-125 (cutoff 35 IU/L): AUC for A2160 versus CA-125,0.92 versus 0.67; PPV 95% versus 64%; and NPV 85% versus 58%. In addition, fully-sialylated glycans had a higher accuracy for diagnosing EOC as compared to partially-sialylated glycans of alpha-chain of complement 4-binding protein. Our study suggested that A2160 may be a useful biomarker to distinguish early-stage OCCC from endometrioma. This new biomarker can be potentially applied for the monitoring of endometrioma patients, making possible the early diagnosis of OCCC.
登录
查看更多内容
影响因子：
4.4
作者：
Holmberg, MT;Blom, AM;Meri, S
通讯作者：
Meri, S
影响因子：
254.7
作者：
Siegel, Rebecca;Naishadham, Deepa;Jemal, Ahmedin
通讯作者：
Jemal, Ahmedin
影响因子：
20.3
作者：
Sorensen, Anne Louise;Rumjantseva, Viktoria;Hoffmeister, Karin M.
通讯作者：
Hoffmeister, Karin M.
定量糖蛋白组学最新进展
影响因子：
3
作者：
Zhang, Ying;Yin, Hongrui;Lu, Haojie
通讯作者：
Lu, Haojie
DOI：
10.1016/s0002-9378(97)70550-7
发表时间：
1997-03-01
影响因子：
9.8
作者：
Brinton, LA;Gridley, G;Bergqvist, A
通讯作者：
Bergqvist, A